BRAF NP_004324.2:P.V600X

Clinical trials for BRAF NP_004324.2:P.V600X explained in plain language.

Never miss a new study

Get alerted when new BRAF NP_004324.2:P.V600X trials appear

Sign up with your email to follow new studies for BRAF NP_004324.2:P.V600X, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New Triple-Threat cancer therapy enters first human safety tests

Disease control Ongoing

This early-stage trial is testing the safety and best dose of a three-drug combination (vemurafenib, cetuximab, and irinotecan) for patients with advanced solid tumors that have spread and carry a specific BRAF gene mutation. The goal is to see if combining these drugs—two that b…

Matched conditions: BRAF NP_004324.2:P.V600X

Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Mar 25, 2026 14:07 UTC

BRAF NP_004324.2:P.V600X

Get alerted when new BRAF NP_004324.2:P.V600X trials appear

New Triple-Threat cancer therapy enters first human safety tests